When Insilico Medicine announced that its generative AI platform had "discovered" a promising drug candidate for pulmonary fibrosis, the company's enthusiasm reflected a broader trend in biotech: AI systems are accelerating drug development at unprecedented speeds. Yet the press release's language—crediting the AI itself as the discoverer—exposed a legal ambiguity that patent offices globally are only beginning to address. Unlike traditional patents, where human inventors are legally required on filings, there is currently no consensus framework for attributing discovery to artificial systems. The U.S. Patent and Trademark Office, European Patent Office, and UK Intellectual Property Office have taken divergent approaches, with some maintaining that only humans can be listed as inventors while others explore more flexible interpretations.

The stakes extend beyond semantics. If AI systems are recognized as inventors, questions cascade through the entire intellectual property ecosystem: Do companies own the patents outright, or do AI developers retain rights? How are royalties distributed? What happens to trade secret protections when algorithms operate as black boxes? The biotech industry faces competitive pressures—companies claiming AI-discovered drugs may attract venture capital and regulatory priority—while patent law hasn't caught up. The FDA doesn't currently differentiate between traditionally discovered and AI-designed drugs during approval, but the attribution question matters for licensing, liability, and determining who can manufacture generic versions after patent expiration.

Legal experts warn that ad-hoc solutions risk creating inconsistent precedent. Patent attorneys note that current filings list human researchers as inventors even when AI did substantial work, a workaround that obscures actual contribution while potentially exposing companies to future challenges from co-inventors claiming inadequate recognition. The European Patent Office's 2022 decision to reject patents listing AI as the sole inventor suggested a preference for human-centric frameworks, yet this could disadvantage companies investing heavily in autonomous discovery systems. Regulatory clarity is urgent: without it, biotech firms may avoid publicizing AI's role to sidestep legal uncertainty, paradoxically slowing transparency about how medicines are actually developed and potentially complicating FDA evaluations that depend on understanding discovery methodology.